Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Alland
Rbhs New Jersey Medical School, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cepheid Inc
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
This proposal will use conventional and novel microbiological assay to examine the drug-resistance phenotype of TB relapse/treatment failure cases and cured controls. It will also use both targeted DNA sequencing and transcriptome analysis (of the Mtb bacilius) to identify the genetic bases for these differences
The Xpert assay is marketed by Cepheid and based on RU patents. Cepheid pays licensing fees to RU as part of a patent pool. The tests being developed in the current project may use molecular beacons resulting in Rutgers, he, and his lab benefiting. In addition, there are two pending Rutgers University patent applications on probes and primers to detect drug resistance in Mtb. Some of the probes and primers are being used in the assay being developed in the current study. Dr. Alland benefits from the development of this technology through his share of license fees paid to Rutgers on his behalf.
Patents are as follows:
1) Non-competitive co-amplification methods
Active
6,461,817
Invention: uses molecular beacons to quantitate amounts of target very precisely in a PCR reaction
2) "Assays for short sequence variants"
Pending in US; Awarded in Europe.WO0131062
Invention: Uses sloppy molecular beacons to identify mutations in PCR amplicons
3)"(b)(4)"
Pending
invention: Primers and probes to identify drug resistance mutations in mycobacterium tuberculosis
On demand blood tests for select agent diagnosis
This project will develop blood tests that can detect infections caused by a bioterrorism attack quickly enough to enable life-saving treatment. The tests will be easy to use and they will be designed so that they can be quickly manufactured if a bioterrorism attack should occur.
Filed on October 26, 2015.
Tell us what you know about David Alland's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Alland filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Alland | Rbhs New Jersey Medical School | Conflict of Interest | Cepheid Inc | $20,000 - $39,999 |
| David Alland | Rbhs New Jersey Medical School | Conflict of Interest | Rutgers, The State University of New Jersey | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.